» Articles » PMID: 26718405

Upregulation of Basolateral Small Conductance Potassium Channels (KCNQ1/KCNE3) in Ulcerative Colitis

Overview
Publisher Elsevier
Specialty Biochemistry
Date 2016 Jan 1
PMID 26718405
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Basolateral K(+) channels hyperpolarize colonocytes to ensure Na(+) (and thus water) absorption. Small conductance basolateral (KCNQ1/KCNE3) K(+) channels have never been evaluated in human colon. We therefore evaluated KCNQ1/KCNE3 channels in distal colonic crypts obtained from normal and active ulcerative colitis (UC) patients.

Methods: KCNQ1 and KCNE3 mRNA levels were determined by qPCR, and KCNQ1/KCNE3 channel activity in normal and UC crypts, and the effects of forskolin (activator of adenylate cyclase) and UC-related proinflammatory cytokines on normal crypts, studied by patch clamp recording.

Results: Whereas KCNQ1 and KCNE3 mRNA expression was similar in normal and UC crypts, single 6.8 pS channels were seen in 36% of basolateral patches in normal crypts, and to an even greater extent (74% of patches, P < 0.001) in UC crypts, with two or more channels per patch. Channel activity was 10-fold higher (P < 0.001) in UC crypts, with a greater contribution to basolateral conductance (5.85 ± 0.62 mS cm(-2)) than in controls (0.28 ± 0.04 mS cm(-2), P < 0.001). In control crypts, forskolin and thromboxane A2 stimulated channel activity 30-fold and 10-fold respectively, while PGE2, IL-1β, and LTD4 had no effect.

Conclusions: KCNQ1/KCNE3 channels make only a small contribution to basolateral conductance in normal colonic crypts, with increased channel activity in UC appearing insufficient to prevent colonic cell depolarization in this disease. This supports the proposal that defective Na(+) absorption rather than enhanced Cl(-) secretion, is the dominant pathophysiological mechanism of diarrhea in UC.

Citing Articles

Causal linkage between type 2 diabetes mellitus and inflammatory bowel disease: an integrated Mendelian randomization study and bioinformatics analysis.

Xiao X, Wu X, Yi L, You F, Li X, Xiao C Front Endocrinol (Lausanne). 2024; 15:1275699.

PMID: 38313367 PMC: 10836595. DOI: 10.3389/fendo.2024.1275699.


Kv7 Channels in Lung Diseases.

Mondejar-Parreno G, Perez-Vizcaino F, Cogolludo A Front Physiol. 2020; 11:634.

PMID: 32676036 PMC: 7333540. DOI: 10.3389/fphys.2020.00634.


Structural Basis of Human KCNQ1 Modulation and Gating.

Sun J, MacKinnon R Cell. 2019; 180(2):340-347.e9.

PMID: 31883792 PMC: 7083075. DOI: 10.1016/j.cell.2019.12.003.


Colonic Potassium Absorption and Secretion in Health and Disease.

Rajendran V, Sandle G Compr Physiol. 2018; 8(4):1513-1536.

PMID: 30215859 PMC: 9769410. DOI: 10.1002/cphy.c170030.


K TASK-2 and KCNQ1-KCNE3 K channels are major players contributing to intestinal anion and fluid secretion.

Julio-Kalajzic F, Villanueva S, Burgos J, Ojeda M, Cid L, Jentsch T J Physiol. 2017; 596(3):393-407.

PMID: 29143340 PMC: 5792569. DOI: 10.1113/JP275178.


References
1.
Yang Y, Sigworth F . Single-channel properties of IKs potassium channels. J Gen Physiol. 1998; 112(6):665-78. PMC: 2229447. DOI: 10.1085/jgp.112.6.665. View

2.
Warth R, Riedemann N, Bleich M, Van Driessche W, Busch A, Greger R . The cAMP-regulated and 293B-inhibited K+ conductance of rat colonic crypt base cells. Pflugers Arch. 1996; 432(1):81-8. DOI: 10.1007/s004240050108. View

3.
Matos J, Sausbier M, Beranek G, Sausbier U, Ruth P, Leipziger J . Role of cholinergic-activated KCa1.1 (BK), KCa3.1 (SK4) and KV7.1 (KCNQ1) channels in mouse colonic Cl- secretion. Acta Physiol (Oxf). 2007; 189(3):251-8. DOI: 10.1111/j.1748-1716.2006.01646.x. View

4.
Sandle G, Perry M, Mathialahan T, Linley J, Robinson P, Hunter M . Altered cryptal expression of luminal potassium (BK) channels in ulcerative colitis. J Pathol. 2007; 212(1):66-73. DOI: 10.1002/path.2159. View

5.
Wacker M, Kosloski L, Gilbert W, Touchberry C, Moore D, Kelly J . Inhibition of thromboxane A2-induced arrhythmias and intracellular calcium changes in cardiac myocytes by blockade of the inositol trisphosphate pathway. J Pharmacol Exp Ther. 2009; 331(3):917-24. PMC: 2784712. DOI: 10.1124/jpet.109.157677. View